Restless Legs Syndrome in Cancer Patients: Causes, Risks, and Treatment
In this article
Restless Legs Syndrome (RLS)is a sensorimotor neurological disorder characterized by unpleasant leg sensations—tingling, burning, crawling, or pulling—accompanied by an urge to move to relieve them. It usually becomes more prominent at rest, especially in the evening and at night, and improves temporarily with movement.
In cancer patients, RLS is considered more than a sleep disorder: it is a **systemic problem affecting quality of life, treatment adherence, and overall prognosis**. It occurs particularly with neurotoxic chemotherapy agents (e.g., platinum agents, taxanes, vincristine), **disrupted iron metabolism**, and **chronic inflammation**. Recognizing and managing RLS is therefore an integral part of supportive oncology care.
Prevalence and Clinical Importance
- In the general population: 2–10%
- In all cancer patients: 5–15%
- In patients receiving chemotherapy: 10–20% (particularly with neurotoxic drugs)
- In advanced-stage patients with anemia or kidney failure: Above 20%
In oncology, RLS matters beyond symptomatic discomfort. The chain of **poor sleep quality → chronic fatigue → reduced physical activity → poor nutrition → treatment nonadherence** directly affects overall treatment success. Fatigue and insomnia may also disrupt cytokine balance in the tumor microenvironment by **suppressing the immune system**.
Pathophysiology and Cancer-Related Mechanisms
- Dopaminergic Dysfunction: Reduced activity in brain dopamine pathways is the main mechanism of RLS. Iron deficiency, common in cancer, impairs dopamine synthesis by reducing tyrosine hydroxylase activity.
- The Iron Deficiency–Chronic Inflammation Cycle: Tumor-driven increases in IL-6 increase hepcidin synthesis, inhibiting iron absorption and release. This reduces the iron available to dopaminergic neurons, creating a basis for RLS.
- Chemotherapy-Induced Peripheral Neuropathy: Cisplatin, oxaliplatin, paclitaxel, and vincristine, in particular, cause axonal damage at nerve endings. This creates an RLS-like picture that may be confused with crawling or burning sensations in the legs.
- Nephrotoxicity: In advanced cancers, accumulated uremic toxins disrupt dopaminergic pathways, increasing RLS risk.
- Drug Interactions: SSRI/SNRI antidepressants, dopamine antagonists such as metoclopramide, and antihistamines may worsen symptoms.
Clinical Features
- Unpleasant leg sensations (tingling, burning, pulling, crawling)
- Worsening at rest, temporary relief with movement
- Greater prominence in the evening and at night
- Difficulty falling asleep, frequent waking, morning fatigue
- Sometimes similar sensations in the arms
Diagnosis and Assessment
IRLSSG (International Restless Legs Syndrome Study Group) diagnostic criteria include four main elements:
- Unpleasant leg sensations + an urge to move
- Worsening at rest
- Temporary improvement with movement
- Greater prominence in the evening/night
IRLS (International RLS Rating Scale) is used to determine severity:
- 0–10: Mild
- 11–20: Moderate
- 21–30: Severe
- 31–40: Very severe
In oncology practice, this score guides both **monitoring treatment response** and **medication titration**.
Management and Treatment Approach
A) Lifestyle and Behavioral Interventions
- Regular but not excessive exercise; avoid exercising particularly in the evening
- Morning daylight exposure strengthens circadian rhythms
- Sleep hygiene: consistent sleep times, limiting screens/caffeine/nicotine/alcohol
- Warm baths, leg massage, warm or cold compresses
B) Pharmacological Interventions
- Iron supplementation: IV or oral iron when ferritin is <50–75 ng/mL
- Dopamine agonists: Pramipexole, ropinirole, rotigotine (low doses; monitor augmentation risk)
- Gabapentinoids: Gabapentin, pregabalin (ideal when neuropathy coexists)
- In refractory cases: Short-term, low-dose opioids under the oncology pain team's supervision
C) Correcting Contributing Causes
- Dose modification and supportive treatment for chemotherapy-induced neuropathy
- Treatment of kidney failure and anemia
- Nutritional and vitamin (B12, folate, magnesium) supplements
Clinical Importance in Oncology
Failure to manage RLS in cancer patients directly harms treatment adherence, prognosis, and quality of life :
- Chemotherapy tolerability decreases: Insomnia and fatigue can lead to dose delays or treatment interruptions.
- Immune regulation is disrupted: Sleep deprivation increases IL-6 and TNF-α levels, strengthening inflammatory responses.
- Depression and anxiety risk increases: This reduces patient motivation and self-care behaviors.
- It may complicate pain management in palliative care.
RLS is therefore more than a neurological symptom: **it is a multidimensional clinical factor affecting cancer treatment success.**
Recommendations for Patients
For patients experiencing restless legs syndrome (RLS) during cancer treatment, simple but effective steps may relieve symptoms:
- Develop regular sleep habits ; try to go to bed and wake up at the same time each day.
- Before bed, avoid caffeine, nicotine, and alcohol .
- During the day, do gentle walking or stretching ; avoid excessive fatigue.
- A warm shower or leg massage can relax muscles and provide relief.
- Before bed, stay away from phone, tablet, and computer screens to reduce blue-light stimulation.
- If your doctor recommends it, have your iron, B12, or folate levels checked and correct any deficiencies.
- Tell your doctor if you take medicines such as certain antidepressants or metoclopramide that may trigger RLS.
- Good sleep hygiene and coping with stress support treatment.
Remember: These suggestions are supportive. If symptoms persist, consult your oncologist or neurologist.
References
- Allen RP et al. Restless Legs Syndrome: Diagnostic Criteria and Epidemiology. Sleep Medicine. 2024.
- Manconi M et al. Cancer-related Restless Legs Syndrome and the Role of Iron Metabolism. J Clin Sleep Med. 2023;19(2):255–263.
- Benedetti F et al. Dopaminergic Dysfunction and Iron Deficiency in Chemotherapy-induced RLS. Neurology. 2022;98(10):e1042–e1053.
- Trivedi AK, et al. Sleep Disturbances in Oncology Patients Receiving Neurotoxic Chemotherapy. Support Care Cancer. 2021;29(8):4711–4721.
- Kotagal S. Management of RLS in Cancer Patients: Integrative Approaches. Curr Oncol Rep. 2024.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.